Answer
Women receiving Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead should not breastfeed because of potential adverse reactions in breastfed infants and to avoid transmitting HIV to the infant.
Sources for this answer
- Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead 200 mg/25 mg/25 mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 24Document updated
Sources checked